JP2023542295A5 - - Google Patents

Info

Publication number
JP2023542295A5
JP2023542295A5 JP2023516467A JP2023516467A JP2023542295A5 JP 2023542295 A5 JP2023542295 A5 JP 2023542295A5 JP 2023516467 A JP2023516467 A JP 2023516467A JP 2023516467 A JP2023516467 A JP 2023516467A JP 2023542295 A5 JP2023542295 A5 JP 2023542295A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
linker
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542295A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/050337 external-priority patent/WO2022056494A1/en
Publication of JP2023542295A publication Critical patent/JP2023542295A/ja
Publication of JP2023542295A5 publication Critical patent/JP2023542295A5/ja
Pending legal-status Critical Current

Links

JP2023516467A 2020-09-14 2021-09-14 Glp1ペプチド模倣薬を含む抗体薬物複合体及びその使用 Pending JP2023542295A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063077983P 2020-09-14 2020-09-14
US63/077,983 2020-09-14
PCT/US2021/050337 WO2022056494A1 (en) 2020-09-14 2021-09-14 Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof

Publications (2)

Publication Number Publication Date
JP2023542295A JP2023542295A (ja) 2023-10-06
JP2023542295A5 true JP2023542295A5 (cg-RX-API-DMAC7.html) 2024-09-20

Family

ID=78080567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516467A Pending JP2023542295A (ja) 2020-09-14 2021-09-14 Glp1ペプチド模倣薬を含む抗体薬物複合体及びその使用

Country Status (12)

Country Link
US (2) US12280124B2 (cg-RX-API-DMAC7.html)
EP (1) EP4210767A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542295A (cg-RX-API-DMAC7.html)
KR (1) KR20230070337A (cg-RX-API-DMAC7.html)
CN (1) CN116615251A (cg-RX-API-DMAC7.html)
AU (1) AU2021339892A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191304A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023000678A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023004558A2 (cg-RX-API-DMAC7.html)
IL (1) IL301074A (cg-RX-API-DMAC7.html)
MX (1) MX2023002974A (cg-RX-API-DMAC7.html)
WO (1) WO2022056494A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023542295A (ja) 2020-09-14 2023-10-06 リジェネロン ファーマシューティカルズ,インク. Glp1ペプチド模倣薬を含む抗体薬物複合体及びその使用
CA3243669A1 (en) 2022-03-11 2023-09-14 Regeneron Pharmaceuticals, Inc. ANTI-GLP1R ANTIBODY-DRUG CONJUGATES INCLUDING GLP1 PEPTIDOMIMETS AND THEIR USES
CN119731206A (zh) * 2022-08-01 2025-03-28 先为达生物美国有限公司 抗glp-1r抗体及其用途
IL322391A (en) 2023-02-27 2025-09-01 Regeneron Pharma Liquid-phase peptide-supported synthesis of peptides and peptide-like molecules
CN122295135A (zh) 2023-11-03 2026-06-26 瑞泽恩制药公司 作为glp1r激动剂的肽酸及其抗体-药物缀合物
IL330385A (en) * 2023-12-29 2026-08-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Antibody-polypeptide conjugate and its pharmaceutical use
WO2026024847A2 (en) * 2024-07-23 2026-01-29 Baylor University Chemical probes for microbial mucin degraders in the gut microbiome

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
US20060275288A1 (en) * 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US7985557B2 (en) 2007-05-23 2011-07-26 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
KR101277560B1 (ko) * 2007-12-11 2013-06-25 카딜라 핼쓰캐어 리미티드 글루카곤 안타고니스트 활성 및 glp-1 아고니스트 활성의 펩티드 유사체
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
ES2560807T3 (es) 2008-07-21 2016-02-22 Polytherics Limited Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
FR2937972B1 (fr) 2008-11-04 2013-03-29 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011048614A2 (en) * 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
EP2601298B1 (en) 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
DK2714685T3 (en) 2011-05-27 2017-01-09 Ambrx Inc FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
JP6166728B2 (ja) 2011-10-14 2017-07-19 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
AU2012322934B2 (en) 2011-10-14 2016-09-08 Medimmune Limited Pyrrolobenzodiazepines
CA2850375C (en) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
BR112014013526A8 (pt) 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁(杭州)生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
WO2015187596A2 (en) 2014-06-02 2015-12-10 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
US9911931B2 (en) 2014-06-26 2018-03-06 Universal Display Corporation Organic electroluminescent materials and devices
GB2551945B (en) * 2015-12-18 2021-09-08 Heptares Therapeutics Ltd Novel GLP-1 receptor agonist peptides
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
EP3419670A2 (en) * 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
EP4480537A3 (en) * 2017-01-17 2025-03-12 Amgen Inc. Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
KR20250008984A (ko) * 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
MX2022014090A (es) 2020-05-12 2023-02-27 Regeneron Pharma Anticuerpos antagonistas anti-glp1r y metodos de uso de los mismos.
JP2023542295A (ja) 2020-09-14 2023-10-06 リジェネロン ファーマシューティカルズ,インク. Glp1ペプチド模倣薬を含む抗体薬物複合体及びその使用

Similar Documents

Publication Publication Date Title
JP2021113191A5 (cg-RX-API-DMAC7.html)
DK2678037T3 (en) Branched linker for protein pharmaceutical conjugates
KR20240095442A (ko) 항체의 특이적 접합
JP4833857B2 (ja) ポリマー残基を生物活性部分に結合するための分岐した分子骨格
CA2991975C (en) Novel linkers and their uses in specific conjugation of drugs to a biological molecule
JP2023524271A5 (cg-RX-API-DMAC7.html)
JP2015526434A5 (cg-RX-API-DMAC7.html)
JP2014520120A5 (cg-RX-API-DMAC7.html)
JP2007526330A5 (cg-RX-API-DMAC7.html)
JP2023129495A5 (cg-RX-API-DMAC7.html)
RU2010149608A (ru) Антиангиогенные соединения
JP2022541517A5 (cg-RX-API-DMAC7.html)
RU2016130121A (ru) Конъюгаты связующего (ADC) с ингибиторами KSP
JP2022095872A5 (cg-RX-API-DMAC7.html)
JP6230199B2 (ja) 標的化送達のための、小分子インテグリンアンタゴニストに共有結合により連結されたキトサン
CN102333788A (zh) 因子viii的修饰
JP2021513990A5 (cg-RX-API-DMAC7.html)
JP2022553702A5 (cg-RX-API-DMAC7.html)
JP2025512735A5 (cg-RX-API-DMAC7.html)
JP2024524613A5 (cg-RX-API-DMAC7.html)
JP2022554094A5 (cg-RX-API-DMAC7.html)
JP2023538524A5 (cg-RX-API-DMAC7.html)
JP2008504237A5 (cg-RX-API-DMAC7.html)
JP2026041725A (ja) 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
JP2022514348A5 (cg-RX-API-DMAC7.html)